SCHEMBL30729993

SCHEMBL30729993

CC(C)(C)OC(=O)N1CCN(c2cncc(C(=O)O)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.50
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
GBA1 P04062 2/20 0.47
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 1/20 0.46
PIK3CA P42336 1/20 0.45
CYP2C19 P33261 1/20 0.44
PDK2 Q15119 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23572682 1.00 GPR119 (0.50) GPR119MAPTALDH1A1LMNAGBA1
SCHEMBL12205269 0.89 GPR119 (0.56) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL23572659 0.88 GPR119 (0.48) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL11355614 0.84 DPP4 (0.47) GPR119MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL11359349 0.84 GPR119 (0.53) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL23839598 0.84 GPR119 (0.52) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL1686074 0.84 GPR119 (0.52) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL32129014 0.84 GPR119 (0.52) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL12225090 0.84 GPR119 (0.52) GPR119MAPTALDH1A1LMNACKS1B
SCHEMBL2064193 0.84 GPR119 (0.45) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 US disclosed
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-09-30 US disclosed
CN-118638043-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-09-13 CN disclosed
CN-118059104-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-05-24 CN disclosed
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-04-25 US disclosed
CN-115175901-B Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-03-22 CN disclosed
US-11883393-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 GPR119 1070/4885MAPT 4164/4885ALDH1A1 1033/4885
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885ALDH1A1 442/4885
US-11883393-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885ALDH1A1 442/4885
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885ALDH1A1 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.